Current Editions
A guide to how recent releases from Anthropic, NVIDIA, Google, OpenAI and Amazon fit into biopharma R&D workflows — and with one another
Discovery & Translation
RNA, other new modalities and cardiorenal programs largely delivered in 1H26, despite uneven antisense performance
Product Development
At oral arguments, judge seemed to lean toward WuXi AppTec on some issues, but didn’t tip his hand on a critical question
Politics, Policy & Law
Founding Partner Jessica Owens details firm’s strategy, how proprietary data beats proprietary models, and gaps in evidence generation: The BioCentury Show
Finance
Product Development
Phase III data suggest little differentiation in efficacy versus Ionis’ Tryngolza, but Redemplo could offer advantages in dosing and hepatic safety
BioCentury Commentary
Geography is becoming a less reliable guide to where important science originates, but translating it across borders demands judgment and disciplined execution
Editor's Commentary
Four companies show how Taiwan is combining global ambition, local capital, and technology strengths to build a biotech hub
Data Byte
Median series A size rose to a decade high of $29.1M as the first-half tally hit a 10-year low; Forbion, Qiming and RA Capital led activity
Discovery & Translation
The U.K. is extending its data offering to researchers far beyond the UK Biobank, with a system that integrates all NHS data across the whole nation
BioCentury’s roundup of translational innovations
Regulation
Among eight positive opinions, Minoryx’s cALD therapy wins backing after a 2024 rejection
Politics, Policy & Law
Healey as Chancellor seen as good choice, but future of life science policy could go either way
Finance
Plus: New spinout Synaptiq addresses rare neuropsychiatric disease; Dimension’s new fund; and more
Plus: PIPEs for reverse mergers as Mentari, Freenome reach NASDAQ; Dyne’s follow-on; and more
Management Tracks
Career spanned three decades in biotech
Biopharma Stock Performers
Use BioCentury's interactive dashboard to view top-performing biopharma stocks for the day and the week.
Product Development
Politics, Policy & Law
Management Tracks
BioCentury ISSN 1097-7201